Sarepta Therapeutics Inc SRPT:NASDAQ

Last Price$68.47NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22

Today's Change-2.83(3.97%)
Bid (Size)$61.93 (1)
Ask (Size)$93.00 (1)
Day Low / High$67.50 - 71.56
Volume699.2 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 05/18/2022


Sarepta Therapeutics Inc ( NASDAQ )

Price: $68.47
Change: -2.83 (3.97%)
Volume: 699.2 K
4:00PM ET 5/18/2022

Intra-Cellular Therapies Inc ( NASDAQ )

Price: $58.50
Change: -0.91 (1.53%)
Volume: 1.3 M
4:00PM ET 5/18/2022

Ionis Pharmaceuticals Inc ( NASDAQ )

Price: $38.39
Change: -0.36 (0.93%)
Volume: 1.2 M
4:00PM ET 5/18/2022

Apellis Pharmaceuticals Inc ( NASDAQ )

Price: $43.52
Change: +1.36 (3.23%)
Volume: 1.6 M
4:00PM ET 5/18/2022

Repligen Corp ( NASDAQ )

Price: $150.55
Change: -4.13 (2.67%)
Volume: 297.8 K
4:00PM ET 5/18/2022

Read more news Recent News

--RBC Capital Adjusts Sarepta Therapeutics Price Target to $155 From $150, Maintains Outperform Rating
10:15AM ET 5/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Loss $-0.56
4:51PM ET 5/04/2022 MT Newswires


-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Loss $-0.56
4:51PM ET 5/04/2022 MT Newswires


-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Reports Q1 Revenue $210.8M, vs. Street Est of $208.2M
4:51PM ET 5/04/2022 MT Newswires


View all Commentary and Analysis

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q1 2022 Results - Earnings Call Transcript
12:29AM ET 5/05/2022 Seeking Alpha

Sarepta: The DMD Leader
1:05AM ET 4/26/2022 Seeking Alpha

Regenxbio: Is The Ultimate Catalyst Coming?
1:38PM ET 4/20/2022 Seeking Alpha

4 Genomic Companies With Upcoming Catalysts
8:07AM ET 4/07/2022 Seeking Alpha

Company Profile

Business DescriptionSarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA. View company web site for more details
Address215 First Street
Cambridge, Massachusetts 02142
Number of Employees499
Recent SEC Filing05/04/202210-Q
President, Chief Executive Officer & DirectorDouglas S. Ingram
Executive VP, Chief Financial & Accounting OfficerIan M. Estepan
Chief Scientific Officer & Executive VPLouise Rodino-Klapac
Chief Customer Officer & Senior Vice PresidentDallan Murray

Company Highlights

Price Open$70.49
Previous Close$68.47
52 Week Range$61.28 - 101.24
Market Capitalization$6.0 B
Shares Outstanding87.5 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.27
Beta vs. S&P 500N/A
Revenue$301.0 M
Net Profit Margin-50.80%
Return on Equity-58.98%

Analyst Ratings as of 03/02/2022

Consensus RecommendationConsensus Icon
Powered by Factset